The Stratified Medicine Core Laboratory (SMCL) Next Generation Sequencing hub is strategically placed in the academic department of Medical Genetics on the Cambridge Biomedical Campus.
The primary aim of the hub is to provide clinical grade NGS services to researchers both on campus and in the wider scientific community (academic & industry based), with a focus on support of translational research.
We can provide a complete ‘end to end’ service, encompassing nucleic acid extraction and sample QC, full library preparation & sequencing and bioinformatics analysis & support. We can also offer advice on experimental and project design, and tailor services to specific project needs.
Academic Laboratory of Medical Genetics,
Box 238, Lv 6 Addenbrooke’s Treatment Centre, Addenbrooke’s Hospital,
Cambridge. CB2 0QQ
Dr Ana Luisa Toribio
Phone: 07740 542495
Request a quote for your Project
About our Laboratory
The initial funding for the facility was received as part of an MRC Clinical Research Infrastructure Initiative which led to the creation of high-tech clinical research facilities within the Cambridge BRC. This covered three main themes; Stratified Medicine Core Laboratory, a centre for Molecular Imaging and a high-performance hub for informatics.
The hub also receives funding by the NIHR through the Cambridge Biomedical Research Centre as part of the Genetics and Genomics theme.
The SMCL NGS hub was subsequently established in mid-2015 and is hosted by the Academic department of Medical Genetics and uniquely housed in the Genetics Laboratories of the East Midlands and East of England NHS Genomic Laboratory Hub (EMEE GLH).
The SMCL NGS Hub core facilities comprise a suite of Illumina NGS platforms (MiSeq, NextSeq 500 & HiSeq 4000), which allow us to offer a comprehensive range of sequencing services.
We also currently conduct routine clinical sequencing for CUHT customers including the EMEE GLH and the Addenbrooke’s Hospital Histocompatibility and Immunogenetics (Tissue Typing) laboratory and for national and international clinical trials through the Cancer Molecular Diagnostics Laboratory (CMDL).